Galera Therapeutics, Inc.
GRTX evidence brief
What we can confirm
- BioSniper Score:
- 7.1 / 10
- Market Cap:
- $3.38B
- Cash Runway:
- 18.9 mo
What it means
What to watch
Prepared research question
What matters most for GRTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · GRTX
Galera Therapeutics, Inc. (GRTX) is a biotechnology company that, after discontinuing its earlier pipeline, acquired Nova Pharmaceuticals in December 2024 to focus on a pan-NOS inhibitor for advanced breast cancers, and in April 2026 entered into a merger agreement with Obsidian Therapeutics.
Key risk: Limited cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Mar 31, 2026.
Tracking 4 pipeline candidates · 1 clinical trial for Galera Therapeutics, Inc..
Galera Therapeutics, Inc. (GRTX) is a biotechnology company that, after discontinuing its earlier pipeline, acquired Nova Pharmaceuticals in December 2024 to focus on a pan-NOS inhibitor for advanced breast cancers, and in April 2026 entered into a merger agreement with Obsidian Therapeutics.
- Galera completed the acquisition of Nova Pharmaceuticals on December 30, 2024, shifting its strategic focus to a pan-inhibitor of nitric oxide synthase (NOS) for metaplastic breast cancer (MpBC) and other refractory subsets of triple-negative breast cancer (TNBC) [sec_mda · as of 2026-05-14].
- The lead program is a Phase 1/2 investigator-sponsored trial of the pan-NOS inhibitor in combination with nab-paclitaxel and alpelisib for MpBC, funded by an NIH grant to Houston Methodist [sec_mda · as of 2026-05-14].
- In April 2026, Galera entered into an Agreement and Plan of Merger with Obsidian Therapeutics, Inc., a privately-held company based in Cambridge, Massachusetts [sec_mda · as of 2026-05-14].
- Galera sold its earlier assets to Biossil for an upfront payment of $3.5 million and is eligible for up to $105.0 million in contingent value rights upon achievement of future milestones [sec_mda · as of 2026-05-14].
- As of 2026-03-31, Galera reported cash & equivalents of $5.5M, net income of -$1.6M, and shareholders' equity of $0.7M [sec].
What works
- Galera has secured a funded Phase 1/2 investigator-sponsored trial for its lead pan-NOS inhibitor, with drug supply covered by an NIH grant, reducing near-term development costs [sec_mda · as of 2026-05-14].
- The company retains potential upside from the Biossil asset sale, including contingent value rights of up to $105.0 million upon achievement of regulatory and commercial milestones [sec_mda · as of 2026-05-14].
- A second trial for the pan-NOS inhibitor is being planned in TNBC in collaboration with the I-SPY 2 consortium, contingent on securing additional capital [sec_mda · as of 2026-05-14].
What to weigh
- Galera's cash position is very limited at $5.5M as of 2026-03-31, and the company acknowledges it must secure additional capital to fund planned trials [sec_mda · as of 2026-05-14].
- The company has a history of discontinued business activities and limited resources, and its stockholders previously rejected a plan of dissolution in October 2024 [sec_mda · as of 2025-03-31].
- The lead program is still in Phase 1/2 and is investigator-sponsored, meaning Galera has limited control over trial execution and timelines [sec_mda · as of 2026-05-14].
- Shareholders' equity is only $0.7M as of 2026-03-31, indicating a very thin capital base [sec].
From the filings
Quoted directly from source documents.
Galera's lead program is a Phase 1/2 trial of a pan-NOS inhibitor for MpBC.
“Our lead program is a Phase 1/2 trial of the pan-NOS inhibitor in combination with nab-paclitaxel and alpelisib for MpBC.”
SEC MD&A · May 14, 2026
Galera entered into a merger agreement with Obsidian Therapeutics in April 2026.
“In April 2026 the Company entered into an Agreement and Plan of Merger (the Merger Agreement) with Obsidian Therapeutics, Inc. (Obsidian), a privately-held company based in Cambridge, Massachusetts.”
SEC MD&A · May 14, 2026
Galera sold its earlier assets to Biossil for an upfront payment of $3.5 million and potential milestones.
“We received consideration from Biossil in the form of an upfront payment of $3.5 million and are eligible to receive further payments upon the achievement of future regulatory and commercial milestones and received contingent value rights of up to $105.0 million in the aggregate.”
SEC MD&A · May 14, 2026
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash & equivalents of $5.5M as of 2026-03-31 may not sustain operations without additional capital [sec].
- Dependence on external funding — Planned second trial in TNBC is contingent on securing additional capital [sec_mda · as of 2026-05-14].
- Merger execution risk — The April 2026 merger with Obsidian Therapeutics introduces integration and strategic uncertainty [sec_mda · as of 2026-05-14].
- Thin equity base — Shareholders' equity of only $0.7M as of 2026-03-31 indicates minimal financial cushion [sec].
What to watch
- Progress of the Phase 1/2 investigator-sponsored trial of the pan-NOS inhibitor for MpBC [sec_mda · as of 2026-05-14].
- Outcome of the merger with Obsidian Therapeutics, including any changes to corporate structure or strategy [sec_mda · as of 2026-05-14].
- Ability to secure additional capital to fund the planned I-SPY 2 consortium trial in TNBC [sec_mda · as of 2026-05-14].
- Achievement of regulatory or commercial milestones from the Biossil asset sale that could trigger contingent payments [sec_mda · as of 2026-05-14].
Sources: Pipeline · SEC MD&A · Generated September 25, 2026 · How we verify sources →
Run Galera Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Galera Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
18.9 months
D/E 1.57 · 0% dilution
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
1
Total value held
$4
| Holder | Shares | Value |
|---|---|---|
| ascentis independent advisors | 93 | $4 |
Short Interest
as of May 21, 2026- % of float
- 5.3%
- Days to cover
- 1.2
- Shares short
- 2,123,783
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
GRTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Galera Therapeutics, Inc.?
Galera Therapeutics, Inc. (GRTX) is a biotechnology company that, after discontinuing its earlier pipeline, acquired Nova Pharmaceuticals in December 2024 to focus on a pan-NOS inhibitor for advanced breast cancers, and in April 2026 entered into a merger agreement with Obsidian Therapeutics.
What is Galera Therapeutics, Inc.'s lead drug candidate?
Galera Therapeutics, Inc.'s most advanced tracked candidate is avasopasem (Phase 1) for Hormone receptor positive (HR+) breast cancer.
Who is the CEO of Galera Therapeutics, Inc.?
Dr. John Mel Sorensen M.D. is the chief executive officer of Galera Therapeutics, Inc. (GRTX).
Where is Galera Therapeutics, Inc. headquartered?
Galera Therapeutics, Inc. (GRTX) is headquartered in Malvern, PA, United States.
What therapeutic areas does Galera Therapeutics, Inc. focus on?
Galera Therapeutics, Inc. develops therapies across Oncology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.